KNE.V - Kane Biotech Inc.

TSXV - TSXV Real Time Price. Currency in CAD

Kane Biotech Inc.

290-100 Innovation Drive
Winnipeg, MB R3T 6G2
204 453 1301

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Marc EdwardsPres, CEO & Director257.48kN/AN/A
Mr. Ray DupuisChief Financial Officer162.53kN/AN/A
Mr. Kevin ColePres & CEO of STEM Animal Health Inc372.29kN/AN/A
Dr. Gregory S. Schultz Ph.D.Chief Scientific Officer & Member of Scientific Advisory BoardN/AN/A1950
Lorne GorberInvestor RelationsN/AN/AN/A
Ms. Lori ChristofalosVP of Quality & ComplianceN/AN/AN/A
Ms. Wendy NachtigallDirector of MarketingN/AN/AN/A
Nicole SendeyInvestor Relations AdviserN/AN/AN/A
Mr. Mark Ahrens-TownsendAdvisorN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Corporate Governance

Kane Biotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.